Ovid Therapeutics Inc. Payments to Acquire Debt Securities, Available-for-sale
Ovid Therapeutics Inc. (OVID) reported Payments to Acquire Debt Securities, Available-for-sale of $106.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $102.74M, a 1976.81% increase year-over-year.
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $4.05M, a 17.31% decline year-over-year.
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $77.06M, a 361.09% increase year-over-year.
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $4.95M, a 49.06% decline year-over-year.
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $91.85M, a 25.40% increase from fiscal 2024.
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $73.25M, a 34.86% decline from fiscal 2023.
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $112.44M, a 34.99% decline from fiscal 2022.
- Ovid Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $172.96M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 3 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 9 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $102.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $106.79M 10-Q · filed 2026-08-13 | $183.85M derived: sum of 3 quarters · filed 2026-08-13 | $188.80M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $4.05M 10-Q · filed 2026-05-12 | $81.11M derived: sum of 2 quarters · filed 2026-05-12 | $86.06M derived: sum of 3 quarters · filed 2026-05-12 | $91.01M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $77.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $82.01M derived: sum of 2 quarters · filed 2026-03-18 | $86.96M derived: sum of 3 quarters · filed 2026-08-13 | $91.85M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | $4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $9.89M derived: sum of 2 quarters · filed 2026-08-13 | $14.79M 10-Q · filed 2025-11-12 | $31.50M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $4.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $9.85M 10-Q · filed 2026-08-13 | $26.56M derived: sum of 3 quarters · filed 2026-08-13 | $36.27M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $4.90M 10-Q · filed 2026-05-12 | $21.61M derived: sum of 2 quarters · filed 2026-05-12 | $31.32M derived: sum of 3 quarters · filed 2026-05-12 | $68.35M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $16.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $26.43M derived: sum of 2 quarters · filed 2026-03-18 | $63.45M derived: sum of 3 quarters · filed 2026-03-18 | $73.25M 10-K · filed 2026-03-18 | ||||
| 2024-09-30 | $9.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $46.74M derived: sum of 2 quarters · filed 2025-11-12 | $56.53M 10-Q · filed 2025-11-12 | $115.05M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $37.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $46.82M 10-Q · filed 2025-08-13 | $105.34M derived: sum of 3 quarters · filed 2025-08-13 | $134.69M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $9.79M 10-Q · filed 2025-05-13 | $68.31M derived: sum of 2 quarters · filed 2025-05-13 | $97.66M derived: sum of 3 quarters · filed 2025-05-13 | $112.48M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $58.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $87.87M derived: sum of 2 quarters · filed 2025-03-11 | $102.69M derived: sum of 3 quarters · filed 2025-03-11 | $112.44M 10-K · filed 2025-03-11 | $112.44M 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $29.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $44.17M derived: sum of 2 quarters · filed 2024-11-12 | $53.93M 10-Q · filed 2024-11-12 | $53.93M 10-Q · filed 2023-11-03 | $118.03M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $14.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $24.57M 10-Q · filed 2024-08-13 | $24.57M 10-Q · filed 2023-08-04 | $88.68M derived: sum of 3 quarters · filed 2024-08-13 | $118.12M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $9.76M 10-Q · filed 2024-05-14 | $9.76M 10-Q · filed 2023-05-05 | $73.86M derived: sum of 2 quarters · filed 2024-05-14 | $103.31M derived: sum of 3 quarters · filed 2024-05-14 | $182.72M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $64.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $93.55M derived: sum of 2 quarters · filed 2024-03-08 | $172.96M derived: sum of 3 quarters · filed 2024-03-08 | $172.96M 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | $29.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $108.86M derived: sum of 2 quarters · filed 2023-11-03 | $108.86M 10-Q · filed 2023-11-03 | $108.86M derived: sum of 4 quarters · filed 2023-11-03 | ||||
| 2022-06-30 | $79.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $79.42M 10-Q · filed 2023-08-04 | $79.42M derived: sum of 3 quarters · filed 2023-08-04 | $79.42M derived: sum of 4 quarters · filed 2023-08-04 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-05-05 | $0.00 derived: sum of 3 quarters · filed 2023-05-05 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $0.00 derived: sum of 2 quarters · filed 2023-03-13 | $0.00 10-K · filed 2023-03-13 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$3.00K derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $9.96M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $9.96M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $9.96M 10-Q · filed 2021-08-16 | ||||||
| 2020-03-31 | $9.96M 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | $34.80M 10-K · filed 2021-03-15 | |||||||
| 2018-12-31 | $36.52K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $5.00M derived: sum of 2 quarters · filed 2020-03-11 | $5.00M derived: sum of 3 quarters · filed 2020-03-11 | $50.01M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $4.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $4.96M derived: sum of 2 quarters · filed 2019-11-08 | $49.98M 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $45.01M 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | $45.01M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |